Q4 2024 Earnings Call Transcript February 13, 2025 Pacific Biosciences of California, Inc. beats earnings expectations.

PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation Committee of the Company’s Board of Directors granted a ...

Despite strong Service and other revenues, PacBio reports soft fourth-quarter 2024 results partly due to lower Revio system ...

Canaccord reiterates a Buy rating on PacBio (PACB) with a $3 price target following the company’s Q4 report. The firm says that although PacBio ...

Pacific Biosciences of California, Inc. ( NASDAQ: PACB) Q4 2024 Earnings Conference Call February 13, 2025 4:30 PM ET Todd Friedman - Senior Director, Finance and Investor Relations Christian Henry - ...

CEO Christian Henry highlighted Q4 2024 revenue of $39.2 million, driven by the shipment of 23 Revio systems and the early shipment of seven Vega benchtop platforms, which exceeded schedule. Full-year ...

Genomics company Pacific Biosciences of California (NASDAQ:PACB) in Q4 CY2024, with sales falling 32.8% year on year to ...

MENLO PARK, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter and fiscal year ended December 31, 2024. Revenue of $39.2 million, a 33% ...

After the National Institutes of Health (NIH) announced late Friday that it would be following a Trump administration ...